XBiotech Inc. — FY 2022 Form 10-K
Business context and period. XBiotech is a pre-commercial biopharmaceutical company developing naturally derived “True Human” monoclonal antibodies, including candidates targeting IL-1α and infectious diseases. This summary covers the fiscal year ended December 31, 2022; the filing was signed March 15, 2023. The company reported 85 full-time employees and no approved products or product-sales revenue.
Financial performance and position
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $4.0 million | $18.4 million |
| Gross profit / gross margin | $3.4 million / 83.8% | $12.6 million / 68.4% |
| Research and development expense | $31.5 million | $28.3 million |
| General and administrative expense | $6.3 million | $9.4 million |
| Operating loss | $34.5 million | $25.1 million |
| Net loss | $32.9 million | $17.4 million |
| Net loss per share, basic and diluted | $1.08 | $0.58 |
| Net cash used in operating activities | $14.8 million | Net cash provided of $69.4 million |
- Interest income was $3.8 million, offset in part by a $2.8 million foreign-exchange loss. Income-tax benefit was $0.7 million, compared with $8.0 million in 2021.
- At year-end, cash and cash equivalents were $157.3 million and a one-year interest-bearing time deposit was reported at $60.2 million. Current assets were $219.8 million versus current liabilities of $4.1 million. Total liabilities were $5.7 million; the filing describes the company’s operations and campus as debt-free.
- Cash and cash equivalents declined by $79.7 million during 2022. Investing cash use of $63.9 million mainly reflected the $63.3 million time-deposit purchase; operating activities used $14.8 million. No financing cash flows were reported for 2022.
Material changes versus 2021
- Revenue fell 78%, principally because Janssen-related manufacturing revenue declined from $18.0 million to $4.0 million. The manufacturing arrangement ended in November 2022; 2021 also included $0.4 million of clinical-trial services revenue, with none in 2022.
- Operating expenses were broadly flat at $37.8 million, but the operating loss widened by $9.4 million as revenue declined. R&D expense rose 12%; G&A expense fell 33%.
- Net loss increased by $15.5 million. The smaller tax benefit in 2022 and lower revenue were important differences; 2021 operating cash flow included receipt of approximately $75 million held in escrow from the bermekimab transaction.
- The company completed an expansion of its Austin manufacturing and R&D center. It purchased the one-year time deposit in July 2022 and reported no dividend or share repurchases during the year. The $75 million dividend was paid in July 2021.
Outlook, commentary, and risks
- Management expects no revenue in 2023 and significant, increasing operating losses for the foreseeable future, including higher general and administrative costs amid inflation. It stated that cash and liquid assets should fund operations and anticipated obligations, and that it expects sufficient cash through 12 months from the report date.
- The company reported progress in anti-IL-1α oncology and rheumatology clinical programs, an investigational new drug application for stroke, and continued work on an RSV antibody candidate. Specific milestones, timelines, or quantified pipeline costs are not provided clearly in the supplied filing text.
- XBiotech may be eligible for up to four $150 million milestones, totaling as much as $600 million, related to Janssen’s development and authorization of bermekimab products for non-dermatological indications. Payments depend on Janssen’s discretion and other conditions and may never be received.
- Key risks include clinical-trial failure or delay, regulatory approval uncertainty, no approved products or recurring product revenue, financing needs, competition, reimbursement and commercialization challenges, supply-chain dependence, intellectual-property protection, and reliance on key personnel. The filing also identifies potential COVID-19-related disruption.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at year-end. The 2022 financial statements received an unqualified audit opinion; the auditor reported no critical audit matters. The auditor was not engaged to provide an opinion on internal-control effectiveness.
Important facts for investors to verify
- Confirm the cash runway using cash, the time deposit’s maturity and availability, expected burn, and management’s stated 12-month funding horizon.
- Track clinical and regulatory milestones for the IL-1α, stroke, RSV, and other pipeline programs, including trial enrollment, results, and development costs.
- Review the end of Janssen manufacturing revenue and the conditions and likelihood of any contingent milestone payments.
- Reconcile future operating cash use with management’s stated outlook, particularly as 2023 revenue is not expected and losses are projected to increase.
- Assess the basis and durability of the 2022 tax benefit, including loss carrybacks, valuation allowances, and uncertain tax positions.